

Ref: IIL/22-23/-----

September 16, 2022

**The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi**


**The Director (Enforcement Department),
Securities & Exchange Commission of Pakistan,
7th Floor, NIC Building,
Jinnah Avenue, Blue Area,
Islamabad**

Subject: **Material Information**

Dear Sir,

In accordance with the requirements of applicable provisions of the Securities Act, 2015, Listing Regulations of Pakistan Stock Exchange and other relevant laws, we hereby inform you that the Board of Directors of **Ismail Industries Limited** in their meeting held today on September 16, 2022 at 11:30 a.m. at Company's registered office situated at 17-Bangalore Town, Main Shahrah-e-Faisal, Karachi has approved the following agenda items in accordance with section 199 of the Companies Act, 2017 subject to fulfilment of all requisite legal requirements:

1. The Board has decided to enhance the quantum of long-term equity investment in its subsidiary company M/s. Hudson Pharma (Private) Limited (Hudson Pharma) as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 800,000,000/- (Rupees: Eight hundred million only) to Rs. 1,200,000,000/- (Rupees: One billion two hundred million only). The enhancement of Rs. 400,000,000/- (Rupees: Four hundred million only) is being proposed specifically to meet the current operational expenses / working capital requirements of the Hudson Pharma.
2. The Board has decided to enhance the Cross Corporate Guarantee amount for its subsidiary company M/s. Hudson Pharma (Private) Limited as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 700,000,000/- (Rupees: Seven hundred million only) to Rs. 1,000,000,000/- (Rupees: One billion only).
3. The Board has decided to enhance the quantum of long-term equity investment in its subsidiary company M/s. Ismail Resin (Private) Limited as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 2,500,000,000/- (Rupees: Two billion five hundred million only) to Rs. 3,000,000,000/- (Rupees: Three billion only). The enhancement of Rs. 500,000,000/- (Rupees: Five hundred million only) is being proposed specifically to meet the further estimated cost over-run arises in which main reasons are high inflation and massive devaluation of Pak Rupee.



Head Office: 17 Bangaloro Town, Main Shahrah-e-Faisal, Karachi - 75350, Pakistan.

Tel: +92 21 34311170-77, 34370056-68

Fax: +92 21 34541094, 34547843, 34541095

4. The Board hereby authorized to provide financial assistance to its subsidiary company M/s. Ismail Resin (Private) Limited (Ismail Resin) by way of creation of lien/charge/hypothecation/mortgage/pledge, (ranking/pari passu) over the fixed assets of the Company to the extent of Rs. 7,000,000,000/- (Rupees: Seven billion only) in favor of Banks/Financial Institutions to secure the banking facilities extended to Ismail Resin.”

A disclosure form is enclosed herewith.

Regards,

For Ismail Industries Limited

(Ghulam Farooq)
Company Secretary

Encl: As above

**DISCLOSURE FORM
IN TERMS OF THE SECURITIES ACT, 2015**

Name of Company	Ismail Industries Limited
Date of Report	September 16, 2022
Name of Company as specified in its Memorandum	Ismail Industries Limited
Address of Registered Office	17, Bangalore Town, Main Shakra-e-Faisal, Karachi.
Contact Information	Mr. Ghulam Farooq Company Secretary 17, Bangalore Town, Main Shakra-e-Faisal, Karachi. Telephone number : 021-34311172-5 Fax number : 021-34547843 Email address : secretarialcompliance@ismailindustries.com

Disclosure of inside information by Listed Company in terms of Securities Act, 2015.

1. The Board has decided to enhance the quantum of long-term equity investment in its subsidiary company M/s. Hudson Pharma (Private) Limited (Hudson Pharma) as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 800,000,000/- (Rupees: Eight hundred million only) to Rs. 1,200,000,000/- (Rupees: One billion two hundred million only). The enhancement of Rs. 400,000,000/- (Rupees: Four hundred million only) is being proposed specifically to meet the current operational expenses / working capital requirements of the Hudson Pharma.
2. The Board has decided to enhance the Cross Corporate Guarantee amount for its subsidiary company M/s. Hudson Pharma (Private) Limited as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 700,000,000/- (Rupees: Seven hundred million only) to Rs. 1,000,000,000/- (Rupees: One billion only).
3. The Board has decided to enhance the quantum of long-term equity investment in its subsidiary company M/s. Ismail Resin (Private) Limited as approved by the shareholders in Annual General Meeting of the Company held on October 25, 2021 from Rs. 2,500,000,000/- (Rupees: Two billion five hundred million only) to Rs. 3,000,000,000/- (Rupees: Three billion only). The enhancement of Rs. 500,000,000/- (Rupees: Five hundred million only) is being proposed specifically to meet the further estimated cost over-run arises in which main reasons are high inflation and massive devaluation of Pak Rupee.

Head Office: 17 Bangalore Town, Main Shahrah-e-Faisal, Karachi - 75350, Pakistan.
Tel: +92 21 34311170-77, 34370056-68
Fax: +92 21 34541094, 34547843, 34541095

4. The Board hereby authorized to provide financial assistance to its subsidiary company M/s. Ismail Resin (Private) Limited (Ismail Resin) by way of creation of lien/charge/hypothecation/mortgage/pledge, (ranking/pari passu) over the fixed assets of the Company to the extent of Rs. 7,000,000,000/- (Rupees: Seven billion only) in favor of Banks/Financial Institutions to secure the banking facilities extended to Ismail Resin.

The Company has duly caused this form / statement to be signed on its behalf by the undersigned hereunto duly authorized.

September 16, 2022



Ghulam Farooq
Company Secretary